Clinical Trial Update: Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects [Phase 1]

View source ↗

Summary

An exploratory Phase I open-label non-randomized study of [F18]CP-18 PET imaging in normal individuals and breast cancer patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• [F18]CP-18 PET imaging agent (CP-18)

Snippet

Sponsor: Siemens Molecular Imaging | Conditions: Breast Cancer | Phase 1 | Status: TERMINATED